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journal homepage: www.elsevier .com/locate /y jb inCall for PapersMining the pharmacogenomics literatureWe are inviting submissions for a special issue of the Journal of
Biomedical Informatics on the automatic or semi-automatic extrac-
tion of relationships between biomedical entities relevant to phar-
macogenomics from the research literature. Accepted papers will
focus particularly on methods for the extraction of genotype–phe-
notype, genotype–drug, and phenotype–drug relationships and the
novel use of these relationships for advancing pharmacogenomic
research. Efforts aimed at creating benchmark corpora as well as
comparative evaluation of existing relationship extraction meth-
ods are of special interest.
Pharmacogenomics is the study of how human genetic variation
affects an individual’s response to drugs. It includes a spectrum of
discovery and application, ranging from the discovery of individual
gene–drug interactions, the uncovering of pathways of drug re-
sponse, the use of human and model system genetic variation to
understand the mechanism of drug action, and the understanding
of both the anticipated and unanticipated effects of drugs. The ﬁeld
includes the understanding of the role of gene–drug interactions in
clinical medicine, including the identiﬁcation of study cohorts, the
deﬁnition of target populations, the evaluation of beneﬁt, and the
analysis of research and clinical databases to extract information
about the larger context of drug interactions in different disease
contexts. As such, pharmacogenomics is a timely and important
ﬁeld. The promise that it holds for individualized medicine is cen-
tral as technical advances such as SNP microarrays, whole genome
sequencing and other high-throughput measurement technologies
allow us to predict beneﬁcial, non-beneﬁcial, and deleterious drugs
for speciﬁc individuals based on aspects of both the individual and
the drug.
However, information management in this ﬁeld relies on fairly
traditional means, especially curated databases (PharmGKB, Drug-
Bank, dbGAP, and others), which do not scale to (1) the rapid ex-
pansion of the pharmacogenomics literature in recent years and
(2) the increasingly available volume of full text publications,
which contain more speciﬁc and (potentially) informative facts
than Medline abstracts. Hence, although there is a large demand
and signiﬁcant utility of text analytics for the study of pharmaco-
genomics, the potential of such methods is not fully realized; in
part because the work to date has failed to bridge the two distinct
worlds—that of (bench) molecular biology and that of (clinically
oriented) pharmacology—and because the developers of text ana-
lytics, both in computer science and biomedical informatics, are
not fully aware of this challenging subﬁeld.
The steady stream of work on extracting interactions from text,
the increasing attention in the Semantic Web to capturing facts as
"nano-publications" (individual assertions that are attributable to
authors and traceable in their publications), and efforts to repre-
sent scientiﬁc discourse in a structured manner, all indicate that
the time is ripe for research that goes even beyond the mere ex-
traction of explicitly stated knowledge in documents to linking
text-mined and database elements through formal reasoning todoi:10.1016/j.jbi.2011.02.001uncover implicit and in some sense "new" knowledge. There have
recently been scientiﬁc workshops and sessions at conferences
devoted to text mining in the context of pharmacogenomics,
including the 2010 and 2011 workshops of the Paciﬁc Symposium
on Biocomputing (http://psb.stanford.edu/), which have demon-
strated the emerging critical mass of investigators in this
subspecialty.
In order to advance this agenda, it is also essential that existing
relationship extraction methods be compared to one another and
that a community-wide sharable benchmark corpus emerges
against which such efforts can be compared. We welcome submis-
sions to this special issue that utilize information available at
PharmGKB to compare different relationship extraction methods
and the corresponding "new" knowledge discovery they might
drive. These include curated relationships and annotations of ge-
netic variants available at http://www.pharmgkb.org/resources/
downloads_and_web_services.jsp.
The planned special issue aims to address the gap in coverage of
text mining for pharmacogenomics, as an important initial applica-
tion area of genomics in clinical medicine, and thus an important
translational medicine activity. The technical area of the issue is in-
tended to focus particularly on genotype–phenotype–drug rela-
tionships. It will include broad categories of work that have been
well-studied in the past, speciﬁcally text mining and reasoning,
but will restrict submissions to applications of that work to the
constrained area of pharmacogenomics, and particularly geno-
type–phenotype–drug relationships. For example, topics that are
solicited include: Relation extraction between genotypes, phenotypes, and drugs,
and other semantic classes relevant to pharmacogenomics.
 Corpus development for pharmacogenomics text mining.
 Associating gene variants (mutations, alleles, rs/ss numbers)
to the associated gene name.
 Using text mining to extract information about the associa-
tion of drugs with clinical phenotypes.
 The use of biological networks in combination with text
mining to facilitate discovery.
 Work on the corpus of documents linked to by PharmGKB.
 Reasoning systems applied over the PharmGKB knowledge
base.
 The creation of ontologies to help relate molecular action of
drugs to their clinical effects.
Work on gene taggers alone will not be considered responsive
to this call. The key feature we seek in submissions is the use of
language technologies to understand the molecular basis of drug
response, its variability, and its impact on phenotypes at the mole-
cular, cellular, organ and whole organisms level. Approaches that
combine text-mining and knowledge-based systems are of special
interest.
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All submitted papers will go through a rigorous peer-review
process that will include both programmatic relevance as well as
scientiﬁc quality. All submissions should follow the guidelines for
authors available at the Journal of Biomedical Informatics web site
(http://www.elsevier.com/locate/yjbin). JBI’s editorial policy is also
outlined on that page and will be strictly followed by special issue
reviewers. Note that JBI generally publishes at least one methodo-
logical review paper in each issue of the journal, and we would
welcome a review of the state of the art in text mining for pharma-
cogenomics for this special issue.
Authors may contact the special issue lead editors (kevin.
cohen@gmail.com or russ.altman@stanford.edu) with a proposed
abstract before submission to get a sense for ﬁt between the pro-
posed manuscript and the goals of the special issue.
Submission process
Authors must submit their paper via the online Elsevier Editor-
ial System (EES) at http://ees.elsevier.com/jbi. Authors can register
and upload their text, tables, and ﬁgures, as well as subsequent re-visions, through this website. Potential authors may contact the
Publishing Services Coordinator in the journal’s editorial ofﬁce
(jbi@elsevier.com) for questions regarding this process. When
asked for the category of their submission, they should indicate
that it is for the special issue on Mining the pharmacogenomics
literature (which will appear as ‘‘Pharmacogenomics’’ on the pull-
down menu).
Submission Deadline: March 15, 2011.Guest Editors
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